Justin Petrone
Justin Petrone covers consumer genomics, ancestry testing, and the microarray and biochip sector of the genomics market for GenomeWeb.
Articles Authored by Justin Petrone
Can.Heal has produced a dozen reports that will inform both EU policies and national health strategies for personalized cancer treatment and prevention going forward.
The firm last week announced it received funding that will allow it to complete development of the test, called Myelo-Scan, by the end of 2026.
Investigators from Inserm and Radboud University Medical Center are spearheading the endeavor, called HT-Advance, which is funded by the EU, the UK, and Switzerland.
DNADX will be launched as an RUO test while the firm continues to work toward setting up a US laboratory.

The researchers, based in the UK and Estonia, also recently released a tool to factor genetic ancestry into polygenic score calculations.
New funds will allow the Estonian company to enter new markets in Europe and to invest in its pipeline of polygenic risk score-based tests.
The new tests, once developed, will be used for selecting patients who might best benefit from therapies for kidney disease, nonalcoholic steatohepatitis, and respiratory disease.
The test is already available commercially in Spain, and the company intends to next launch its offering in Italy, as it expands to other European markets.

Elypta Expands Trial for Liquid Biopsy Kidney Cancer Recurrence Test; Plans Bladder Cancer Assay
Premium
Elypta is also developing a third test for the early detection of multiple cancers, which the company believes could eventually be used for routine cancer screening.
The assay underwent clinical validation at three centers in Singapore and 5,248 patients were ultimately screened using the test.